LEAP-015 (MK-7902-015)

Name No. For Patients with Purpose
LEAP-015 (MK-7902-015) 21-34

Previously untreated advanced/ metastatic HER-2 negative gastric/ gasto-esophageal junction (GEJ) cancer.

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer.


DESTINY DS8201-A-U306  

Name No. For Patients with Purpose
DESTINY DS8201-A-U306   21-07

HER-2 positive metastatic and/or unresectable gastric or gasto-esophageal junction (GEJ) cancer

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd), a HER-2 targeting antinbody drug, compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) cancer who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.


BMS CA209-8HW

Name No. For Patients with Purpose
BMS CA209-8HW 18-08

Metastatic colorectal cancer (mCRC)

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).


Astellas 8951-CL-5201

Name No. For Patients with Purpose
Astellas 8951-CL-5201 CTRIAL-IE 18-44

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

This study will asses the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM)


FIDES-01 (Formerly ARQ 087-301)

Name No. For Patients with Purpose
FIDES-01 (Formerly ARQ 087-301) 18-10

Bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion, or, FGFR2 gene mutations or amplifications.

To investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications.


Lithium

Name No. For Patients with Purpose
Lithium 11-32

Advanced oesophago-gastric or colorectal cancer

The purpose of this trial is to determine the safety and efficacy of the drug lithium and the optimum dose when used with standard chemotherapy.


MK3475-937 (KEYNOTE-937)

Name No. For Patients with Purpose
MK3475-937 (KEYNOTE-937) 19-07

Hepatocellular Carcinoma

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation (KEYNOTE-937).